Brief: Clinical Laserthermia Q3 Pre-Tax Loss SEK 17.2 Mln

Clinical Laserthermia Systems AB

17/11/2023 07:34

Nov 17 (Reuters) - Clinical Laserthermia Systems AB
 CLSRb.ST :
    * Q3 SAW CONTINUED REVENUE GROWTH DRIVEN PRIMARILY BY US
MARKET
    * WITH COMPLETION OF RIGHTS ISSUE IN JULY, WE ARE NOW WELL
POSITIONED TO CONTINUE TO GROW ACROSS US AS WELL AS UNLOCK
POTENTIAL OF EUROPE AND ASIA PACIFIC
    * SAW A POSITIVE TREND IN SALES DRIVEN BY COMMERCIAL EFFORTS
IN US
(UROLOGY)
    * PRIMARY FOCUS WILL REMAIN ON US MARKET
    * EXPECT PRODUCT APPROVAL PROCESS IN SINGAPORE IS NEARING
COMPLETION
    * WILL ALSO LOOK AT DEVELOPING ASIA PACIFIC REGION
    * IN EUROPE WE WILL CONTINUE WORK TO ADD NEW CUSTOMERS AND
EXPAND
OUR DISTRIBUTOR NETWORK
    * FINETUNING OF OUR COMMERCIALIZATION ROLL-OUT IS MOVING US
TOWARDS ACHIEVING OUR REVENUE TARGET IN 2025
    * Q3 NET SALES TOTALED SEK 1,978,000 (SEK 884,000)
    * Q3 LOSS AFTER FINANCIAL ITEMS TOTALED SEK -17,247,000 (SEK
-30,374,000)

Source text for Eikon:  ID:nWkr6c3knX 
Further company coverage:  CLSRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))